Learn
The July 2026 FDA peptide vote, explained
By the Everlon founding team · · How we write and review health content
Quick answer On July 23 and 24, 2026, a committee of outside experts that advises FDA looked at seven peptides and, according to news reports, recommended that six of them be added to the list of ingredients compounding pharmacies may use. FDA's own staff had argued against all seven, and the committee only advises: it doesn't approve drugs or change the law. As of October 2026, none of the six is FDA-approved or on FDA's list of ingredients licensed pharmacies may compound with. What came later is a proposal from HHS: in a draft policy published for comment on October 30, 2026, HHS says it does not intend to take enforcement action against compounding the six when strict conditions are met; the draft is not final, and it is not approval.
What the committee is, and what it isn't
The Pharmacy Compounding Advisory Committee, usually shortened to PCAC, is a federal advisory committee of outside experts. It advises FDA on which bulk ingredients should go on the 503A bulks list of substances a licensed compounding pharmacy may use.
It is advisory in the plain sense of the word. The committee does not make law or approve drugs, and FDA's meeting page says its recommendations are non-binding: FDA generally follows them but is not legally required to. FDA announced this meeting in the Federal Register on April 16, 2026.
What the committee did
FDA has posted no minutes, transcript or vote results for this meeting (its page was last updated August 6, 2026). The outcomes below come from news reports (STAT, July 24, 2026; AJMC, July 31, 2026), which agree on every one. This page prints no vote counts, because FDA has published none.
| Peptide | Day | Use FDA reviewed (per FDA's meeting page) | Outcome, as reported |
|---|---|---|---|
| BPC-157 | July 23 | Ulcerative colitis | Recommended |
| KPV | July 23 | Wound-related uses and inflammatory conditions | Recommended |
| TB-500 | July 23 | Wound-related uses | Recommended |
| MOTS-c | July 23 | Obesity and osteoporosis | Recommended |
| Semax | July 24 | Cerebral ischemia, migraine and trigeminal neuralgia | Recommended |
| Epitalon | July 24 | Insomnia | Recommended |
| DSIP (emideltide) | July 24 | Opioid withdrawal, chronic insomnia and narcolepsy | Not recommended |
Each substance was considered as a free base and as an acetate salt; the news reports give one result per substance. The committee voted on a compounding list, not on whether anything is safe or works.
The seven peptides, one by one
A short, neutral note on each.
BPC-157
A lab-made peptide of 15 amino acids. FDA reviewed it for ulcerative colitis and its staff proposed against listing it; the committee recommended it, per the news reports above. As of October 2026 it is not FDA-approved and not on the bulks list; HHS's draft policy would cover it by four routes. Is BPC-157 legal or FDA approved? has the full status, and BPC-157 vs TB-500 compares the two.
KPV
A three-amino-acid fragment of alpha-MSH, a hormone the body makes. FDA reviewed it as a cream or gel for wound-related uses and inflammatory skin conditions, found no study of it in people, and proposed against listing it; the committee recommended it. Not FDA-approved and not on the bulks list as of October 2026; HHS's draft policy would cover it topically and by mouth. What is the KPV peptide?
TB-500
A lab-made, seven-amino-acid fragment of the natural protein thymosin beta-4, which FDA's reviewers say is not the same substance as the full protein. FDA reviewed it for wound-related uses by injection, found no study in people, and proposed against listing it; the committee recommended it. Not FDA-approved and not on the bulks list as of October 2026; HHS's draft policy would cover it by injection. What is TB-500?
MOTS-c
A 16-amino-acid peptide encoded in mitochondrial DNA. FDA reviewed it for obesity and osteoporosis, found no published study of it given to people, and proposed against listing it; the committee recommended it. Not FDA-approved and not on the bulks list as of October 2026; HHS's draft policy would cover it by injection. What is MOTS-c?
Semax
A lab-made peptide built from a fragment of the pituitary hormone ACTH, registered as a drug in Russia according to FDA's briefing and not approved in the United States. FDA reviewed it for cerebral ischemia, migraine and trigeminal neuralgia and proposed against listing it; the committee recommended it. Not on the bulks list as of October 2026; HHS's draft policy would cover it as a nasal form only. What is Semax?
Epitalon
A lab-made peptide of four amino acids, reviewed by FDA for insomnia and recommended by the committee per the news reports; as of October 2026 it is not FDA-approved and not on the bulks list, and HHS's draft policy would cover it by injection, dispensed in intermittent courses.
DSIP (emideltide)
A peptide FDA reviewed for opioid withdrawal, chronic insomnia and narcolepsy. News reports say the committee did not recommend it, the one substance of the seven it turned down, and HHS's draft policy would not cover it. That creates no new prohibition; it means the committee did not back adding it. It shows the committee voted substance by substance.
Why FDA's own reviewers said no
FDA's briefing documents proposed that none of the seven be added to the bulks list: for each, the reviewers concluded that FDA's four criteria (characterization, safety, evidence for the nominated use, and history of use in compounding) weigh against listing it. All seven nominations had been withdrawn earlier in 2026, and FDA brought them to the committee anyway.
What changed after the vote
For the bulks list, nothing:
- the 503A bulks list was not amended, and it is a federal regulation that only notice-and-comment rulemaking can change;
- none of the six was added to FDA's list of ingredients licensed pharmacies may compound with, as of October 2026;
- none of them is an FDA-approved drug;
- none of them moved into Category 1, FDA's interim "we don't intend to act" category, or into either of FDA's other two categories. How the categories work.
The recommendations feed a rulemaking process that had not started when we last checked the Federal Register, on October 21, 2026: there was no proposed rule for any of the six.
What came next is a draft from HHS, the department FDA belongs to, reported by the National Community Pharmacists Association on October 29, 2026. HHS published it for comment (Federal Register, FR Doc. 2026-22192; Docket No. HHS-OASH-2026-0496; October 30, 2026), with a two-week comment period; the notice says it is "not binding on HHS or the public." The draft says HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding any of the six when every condition is met, until a final rule decides each one's place on the bulks list. It is not approval and not a listing. Its routes and conditions. FDA has announced a second meeting, before the end of February 2027, on five other substances (LL-37, injectable GHK-Cu, dihexa, Melanotan II and PEG-MGF). It is a separate proceeding.
Is this right for me?
This page is for anyone who read that FDA "approved peptides". Only a licensed provider who knows your history can tell you whether any treatment suits you, and the answer may be no.
What you can do now:
- Read the page for the peptide you came here about; each one above links to it.
- If a clinic or website offers one of the six, ask how it meets each condition of HHS's draft policy, starting with the route and the prescription. How to get peptides legally explains the difference between a prescription and a "research use only" label.
- Take your goal to your own doctor.
- If you want to hear whether availability changes, use the sign-up at the end of this page. It reserves nothing.
How it works
- Enter your email below. The form at the end of this page asks for your email address and state, and nothing about your health.
- Hear from us only if Everlon offers one of them. We write about availability and nothing else, and you can unsubscribe anytime.
- A licensed provider still decides. Being on the list is not a reservation or a prescription. If Everlon ever offers one, a provider licensed in your state reviews your health history first and can decline.
FAQ
Which peptides did FDA approve in July 2026? None. FDA approved nothing. An advisory committee recommended six of seven peptides for the compounding bulks list, according to news reports; FDA has not listed them, and HHS's draft policy is enforcement discretion, not approval. Being on the bulks list would not make a substance an approved drug in any case.
Does this mean a pharmacy can compound BPC-157 now? Not because of the vote. As of October 2026 FDA had not amended the bulks list, and BPC-157 is not on it. Separately, HHS's draft policy, not final, says HHS does not intend to take enforcement action against BPC-157 compounded under its conditions. The status explainer is here.
Does FDA usually follow the committee? FDA says it generally follows advisory committee recommendations but is not legally bound to. Here FDA's own reviewers proposed the opposite, and FDA has announced no timetable, so the outcome is hard to predict.
How many votes did each peptide get? FDA has not posted a vote record, so this page prints no counts. The outcomes above are as reported by STAT and AJMC.
What should I watch for next? A proposed rule in the Federal Register, with a docket number and a comment deadline, and the final version of HHS's draft policy after its comment period; as written, the draft would last until a final rule.
What this means for you
As of October 2026, none of the six peptides is on FDA's 503A bulks list, the list of ingredients licensed pharmacies may compound with for patients, and only FDA rulemaking changes that. Until a final rule decides, HHS has proposed, in a draft policy, not to take enforcement action against them when its conditions are met; the draft is not final and may change. Compounded medications are not FDA-approved, and products sold online as "research use only" aren't made for people.
Safety information
None of the seven substances the committee reviewed is an FDA-approved drug, and as of October 2026 none of the six that were recommended is on FDA's 503A bulks list, so there is no FDA-approved, labeled product to describe here.
- What FDA has said. FDA's page on substances that may present significant safety risks says, for several of these peptides, that compounded drugs may pose a risk of immunogenicity (an immune reaction to the peptide), may have complexities with peptide-related impurities, and that FDA lacks the information to know whether the drug would cause harm when given to people. Each peptide's own page quotes FDA's statement about it word for word.
- Not a verdict either way. Those statements are not a finding that any of them is harmful, and not a finding that any of them is safe.
- "Research use only" products. They are not prepared by a licensed pharmacy for a named patient, no prescriber reviews your health history, and nothing assures you of what is in them. Everlon never sells "research use only" products.
- Compounded medicines in general. Compounded medications are not FDA-approved, which would remain true even if a licensed pharmacy could one day prepare one of these substances.
If you have used a product sold under one of these names and something feels wrong, stop and contact a doctor; you can also report it to FDA's MedWatch program. If this is a medical emergency, call 911.
Sources
- FDA. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. Federal Register 2026;91:20465. FR Doc. 2026-07361, Docket FDA-2025-N-6895. April 16, 2026, accessed 2026-10-06
- FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (page current as of 08/06/2026), accessed 2026-10-06
- FDA. Briefing Document Introduction, Pharmacy Compounding Advisory Committee, July 23-24, 2026, accessed 2026-10-06
- FDA. FDA Briefing Document: BPC-157 (free base) and BPC-157 acetate. July 23, 2026, accessed 2026-10-06
- FDA. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: Questions, accessed 2026-10-06
- FDA. Early announcement: Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027), accessed 2026-10-06
- FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (interim categories list), updated May 14, 2026, accessed 2026-10-06
- FDA. Interim categories list, version updated April 22, 2026 (archived copy), accessed 2026-10-06
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (page current as of 05/14/2026), accessed 2026-10-06
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026), accessed 2026-10-06
- 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A, accessed 2026-10-06
- STAT. FDA advisory panel rejects compounding of one peptide, backs another. July 24, 2026 (news report), accessed 2026-10-06
- HHS. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix B; no issue or effective date printed), accessed 2026-10-29
- AJMC. FDA Panel Backs 6 Peptides for Compounding. July 31, 2026 (news report), accessed 2026-10-06
- National Community Pharmacists Association (NCPA). Newsroom report on enforcement discretion for compounding six peptides. October 29, 2026 (news report), accessed 2026-10-29
Compounded medications are prepared by a state-licensed 503A compounding pharmacy and are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.
Individual results vary. Treatment is prescribed only when clinically appropriate, and a prescription is never guaranteed. This article is for education and is not a substitute for professional medical advice, diagnosis, or treatment. If this is a medical emergency, call 911.